The news is directly related to Amgen as RBC Capital maintains its 'Sector Perform' rating on the company and raises the price target. This suggests that the analyst sees potential in the company but does not expect it to outperform its sector. The slight increase in price target may have a neutral impact on the stock as it does not indicate a significant change in the company's valuation.